

Alix (G-10): sc-166952



The Power to Question

BACKGROUND

ALG-2-interacting protein (Alix), also designated programmed cell death 6-interacting protein (PDCD6-interacting protein), is a cytoplasmic protein. Alix interacts with apoptosis-associated proteins (ALG-2 and PDCD6) and with the endocytosis-regulator CIN85. Additionally, Alix interacts with the endosomal sorting complexes required for transport (ESCRT) proteins (Tsg101 and CHMP4) and can associate with HIV-1. The endophilins (SH3P4, SH3P8 and SH3P13), enzymes that change curvature of the membrane that are required for early and late steps of coated vesicle formation, also bind to Alix. Alix is involved in the concentration and sorting of cargo proteins of the multivesicular body for incorporation into vesicles.

CHROMOSOMAL LOCATION

Genetic locus: PDCD6IP (human) mapping to 3p22.3.

SOURCE

Alix (G-10) is a mouse monoclonal antibody raised against amino acids 463-732 mapping near the C-terminus of Alix of human origin.

PRODUCT

Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Alix (G-10) is available conjugated to agarose (sc-166952 AC), 500 µg/0.25 ml agarose in 1 ml, for IP; to HRP (sc-166952 HRP), 200 µg/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-166952 PE), fluorescein (sc-166952 FITC), Alexa Fluor® 488 (sc-166952 AF488), Alexa Fluor® 546 (sc-166952 AF546), Alexa Fluor® 594 (sc-166952 AF594) or Alexa Fluor® 647 (sc-166952 AF647), 200 µg/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor® 680 (sc-166952 AF680) or Alexa Fluor® 790 (sc-166952 AF790), 200 µg/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA

APPLICATIONS

Alix (G-10) is recommended for detection of Alix of human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for Alix siRNA (h): sc-60149, Alix shRNA Plasmid (h): sc-60149-SH and Alix shRNA (h) Lentiviral Particles: sc-60149-V.

Molecular Weight of Alix: 95 kDa.

Positive Controls: THP-1 cell lysate: sc-2238, HEL 92.1.7 cell lysate: sc-2270 or K-562 whole cell lysate: sc-2203.


STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



Alix (G-10): sc-166952. Western blot analysis of Alix expression in K-562 (A), HUV-EC-C (B), T-47D (C), U-87 MG (D) and HEL 92.1.7 (E) whole cell lysates.



Alix (G-10) Alexa Fluor® 790: sc-166952 AF790. Direct near-infrared western blot analysis of Alix expression in THP-1 (A), K-562 (B) and T-47D (C) whole cell lysates. Blocked with UltraCruz® Blocking Reagent: sc-516214. Cruz Marker™ Molecular Weight Standards detected with Cruz Marker MW Tag-Alexa Fluor® 680: sc-516730.

SELECT PRODUCT CITATIONS

- Amodio, G., et al. 2011. Proteomic signatures in thapsigargin-treated hepatoma cells. *Chem. Res. Toxicol.* 24: 1215-1222.
- Madrigal-Matute, J., et al. 2015. Thioredoxin-1/peroxiredoxin-1 as sensors of oxidative stress mediated by NADPH oxidase activity in atherosclerosis. *Free Radic. Biol. Med.* 86: 352-361.
- Staubach, S., et al. 2016. Differential proteomics of urinary exovesicles from classical galactosemic patients reveals subclinical kidney insufficiency. *J. Proteome Res.* 15: 1754-1761.
- Nakurte, I., et al. 2018. Colorectal cancer cell line SW480 and SW620 released extracellular vesicles: focus on hypoxia-induced surface proteome changes. *Anticancer Res.* 38: 6133-6138.
- Bliss, C.M., et al. 2020. Targeting antigen to the surface of EVs improves the *in vivo* immunogenicity of human and non-human adenoviral vaccines in mice. *Mol. Ther. Methods Clin. Dev.* 16: 108-125.
- Shephard, A.P., et al. 2021. Stroma-derived extracellular vesicle mRNA signatures inform histological nature of prostate cancer. *J. Extracell. Vesicles* 10: e12150.
- Sadovska, L., et al. 2022. Comprehensive characterization of RNA cargo of extracellular vesicles in breast cancer patients undergoing neoadjuvant chemotherapy. *Front. Oncol.* 12: 1005812.
- Farhat, W., et al. 2022. Doxorubicin-loaded extracellular vesicles enhance tumor cell death in retinoblastoma. *Bioengineering* 9: 671.
- Bajo-Santos, C., et al. 2023. Plasma and urinary extracellular vesicles as a source of RNA biomarkers for prostate cancer in liquid biopsies. *Front. Mol. Biosci.* 10: 980433.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.